Is it safe to get Strattera online?

If you’re exploring treatment options for ADHD, you’ve likely wondered: Can I really get prescribed ADHD medication through a video call? The short answer is yes—and for non-stimulant medications like Strattera (atomoxetine), the process is often more straightforward than you might think.

Unlike stimulant medications such as Adderall or Ritalin, non-stimulant ADHD medications aren’t controlled substances under federal law. This means they’re not subject to the same strict prescribing rules that have made telehealth ADHD treatment feel like navigating a maze of regulations. Whether you’re seeking treatment for the first time or looking to switch from a stimulant medication, understanding how telehealth prescribing works—and what varies from state to state—can help you access care with confidence.

Understanding Non-Stimulant ADHD Medications and Telehealth

What Makes Non-Stimulants Different?

Strattera (atomoxetine) stands apart from traditional ADHD medications because it’s not a controlled substance. The Drug Enforcement Administration (DEA) doesn’t classify it as Schedule II like Adderall or Vyvanse, which means:

• No federal in-person exam requirement for prescribing
• Flexible refill options (up to 90-day supplies are common)
• Lower regulatory scrutiny compared to stimulant prescriptions
• No risk of physical dependence or abuse potential

This classification makes non-stimulants particularly well-suited for telehealth prescribing. While stimulant medications currently exist in a temporary regulatory gray area (with COVID-era prescribing flexibilities extended only through December 31, 2025), non-stimulants can be prescribed via telehealth without these additional federal restrictions.

How Effective Are Non-Stimulants?

Many patients assume that only stimulants effectively treat ADHD. While stimulants do work faster—often within hours—non-stimulants like Strattera offer distinct advantages:

• Sustained 24-hour symptom control without the ‘on-off’ effect of stimulants
• Lower cardiovascular side effects for patients with heart concerns
• Reduced anxiety in some patients (stimulants can sometimes worsen anxiety)
• No potential for misuse or diversion, important for those with substance use history
• Improvement in emotional regulation and impulse control

Strattera typically takes 4-6 weeks to reach full effectiveness, so patience is important. For many adults with ADHD—particularly those who also experience anxiety or have concerns about stimulant side effects—non-stimulants represent an excellent first-line treatment option.

Free consultations available with select providers only.

Get a free consultation

And find an affordable, caring specialist.

Find a provider

Free consultations available with select providers only.

Federal Regulations: What You Need to Know in 2025

The Current State of DEA Telehealth Rules

The regulatory landscape for telehealth prescribing has been evolving rapidly since 2020. Here’s where things stand as of December 2025:

For Stimulant Medications (Schedule II):The DEA’s ‘Third Temporary Extension’ allows providers to prescribe controlled substances via telehealth without a prior in-person exam through December 31, 2025. However, this flexibility is temporary. The DEA has signaled a likely fourth extension for 2026, but nothing is finalized yet. Without congressional action or another extension, the traditional Ryan Haight Act requirements—mandating an in-person medical evaluation before any online controlled substance prescription—would resume.

For Non-Stimulant Medications:Non-stimulants like Strattera have never been subject to these federal restrictions. Because they’re not controlled substances, the Ryan Haight Act’s in-person exam requirement doesn’t apply. This means telehealth prescribing of non-stimulants has been consistently legal, even before the pandemic.

What Providers Must Still Follow

Even though federal law doesn’t impose special restrictions on non-stimulant telehealth prescribing, legitimate providers still must:

• Establish a proper provider-patient relationship through a comprehensive video evaluation
• Follow DSM-5 diagnostic criteria for ADHD (not just a quick questionnaire)
• Maintain state medical licensure where the patient is located
• Use appropriate telehealth platforms that meet HIPAA privacy standards
• Document the evaluation thoroughly, just as they would for in-person visits

At Klarity Health, our providers conduct comprehensive evaluations that mirror in-person standards of care, ensuring you receive an accurate diagnosis and appropriate treatment plan—not just a prescription mill experience.

State-by-State Telehealth Rules: Where You Can Get Treatment

While federal law permits non-stimulant prescribing via telehealth nationwide, state regulations add another layer of requirements. Here’s what you need to know about key states:

States with Minimal Telehealth Restrictions

CaliforniaCalifornia takes a progressive approach to telehealth. There’s no state-mandated in-person exam requirement for non-controlled medications. Providers must establish a ‘good faith exam’ via telehealth, which includes a thorough video consultation. California law treats telehealth visits equivalently to in-person visits for establishing care relationships. The state is also considering AB 1503, which would further clarify that telehealth exams satisfy prescription requirements for non-controlled medications.

IllinoisIllinois stands out for its telehealth-friendly policies and full practice authority for nurse practitioners. The state has no in-person requirements for ADHD treatment via telehealth, whether using stimulants or non-stimulants. Telehealth parity laws enacted in 2021 made virtual care access permanent, ensuring that patients can receive the same standard of care remotely as they would in person.

PennsylvaniaPennsylvania made telehealth permanent through its Telemedicine Act and doesn’t require in-person visits for ADHD medication prescribing. The state focuses its regulatory attention on opioids and benzodiazepines, leaving ADHD treatment pathways relatively unrestricted. Pennsylvania’s collaborative practice model means both physicians and nurse practitioners can prescribe non-stimulants via telehealth effectively.

States with Moderate Requirements

FloridaFlorida presents an interesting case. While the state prohibits telehealth prescribing of Schedule II stimulants in most circumstances, there’s a critical exception for psychiatric conditions. Since ADHD is classified as a psychiatric disorder, stimulant prescriptions via telehealth are permitted under this exception. For non-stimulants like Strattera, Florida imposes no special restrictions whatsoever.

Florida does require checking the Prescription Drug Monitoring Program (PDMP) before every controlled substance prescription, but this doesn’t affect Strattera prescriptions. Patients should ensure their telehealth provider is licensed in Florida and uses video consultation (phone-only visits don’t meet Florida’s definition of telehealth for controlled substances).

TexasTexas welcomes telehealth for mental health conditions, including ADHD. The state explicitly allows telemedicine for behavioral health and chronic care management. There’s no blanket in-person requirement for ADHD treatment.

However, Texas has unique restrictions on who can prescribe certain medications. Nurse practitioners and physician assistants cannot prescribe Schedule II stimulants (like Adderall) in typical outpatient settings—they’re limited to hospital or hospice contexts for these medications. This doesn’t affect Strattera prescriptions, which NPs and PAs can prescribe under their collaborative practice agreements. If you need stimulant medication via telehealth in Texas, you’ll need to see a physician (MD or DO).

GeorgiaGeorgia allows telehealth ADHD treatment with no state-imposed in-person requirements for non-controlled medications. However, the state’s restrictions on nurse practitioner prescribing authority are among the strictest in the nation. Georgia NPs cannot prescribe Schedule II controlled substances at all, even with physician collaboration. For patients seeking Strattera or other non-stimulants, Georgia NPs can prescribe under their collaborative agreements. For stimulant medications, you’ll need to see a physician.

States with Stricter Telehealth Requirements

New YorkNew York implemented significant telehealth restrictions in 2025. The state now requires an initial in-person medical evaluation before prescribing any controlled substance via telehealth. This rule effectively reinstates Ryan Haight Act standards at the state level, even while federal flexibilities remain in place.

Importantly for our discussion: this restriction doesn’t apply to non-stimulant medications like Strattera. Since Strattera isn’t a controlled substance, New York patients can receive it via telehealth without any mandatory in-person visit. However, if you also need a stimulant medication in New York, you’ll need to complete an in-person exam first (with your telehealth provider or another licensed practitioner).

AlabamaAlabama maintains some of the strictest telehealth prescribing rules in the country. The state requires patients receiving ongoing telehealth treatment to have an in-person visit within 12 months after four telehealth consultations for the same condition.

However, there’s a significant exception: mental health services are exempt from this annual in-person requirement. Since ADHD treatment falls under psychiatric/mental health care, many patients can receive continuous telehealth treatment for ADHD without the 12-month in-person mandate. That said, Alabama also has unusual rules for initial controlled substance prescriptions—requiring a licensed medical professional to be physically present with the patient during the telehealth visit if there hasn’t been a prior in-person exam. These rules primarily affect stimulant prescriptions; Strattera prescriptions face no such requirements.

New HampshireNew Hampshire recently updated its telehealth laws in a more patient-friendly direction. As of August 2025, the state removed prior in-person requirements and now only mandates at least an annual follow-up evaluation (which can be conducted via telehealth) for patients receiving controlled medications via telemedicine. This represents significant improvement over previous restrictions and makes New Hampshire one of the more progressive states for telehealth ADHD treatment going into 2026.

Understanding Prescription Monitoring Programs (PMPs)

Many states require providers to check their Prescription Drug Monitoring Program database before prescribing controlled substances. Here’s what this means for non-stimulant prescriptions:

When PMP Checks Are Required

Definitely Required:

• Florida: Every controlled substance prescription
• Pennsylvania: First prescription and every 90 days for ongoing therapy
• New Hampshire: Every controlled substance prescription
• Georgia: First prescription and every 90 days

Typically Required:Most other states mandate PMP checks for Schedule II opioids and benzodiazepines, with varying requirements for other controlled substances.

What This Means for Strattera Patients

Since Strattera isn’t a controlled substance, state law doesn’t typically require a PMP check before prescribing it. However, responsible providers—including those at Klarity Health—often review prescription history as part of comprehensive care. This helps identify:

• Previous ADHD treatments you’ve tried
• Potential drug interactions with current medications
• Any patterns suggesting substance use concerns
• Overall medication management needs

This voluntary review is about ensuring your safety and optimizing treatment, not regulatory compliance.

Who Can Prescribe ADHD Medications via Telehealth?

Understanding provider qualifications matters, especially since prescribing authority varies by medication type and state.

Physicians (MD/DO)

In all 50 states, licensed physicians can prescribe both stimulant and non-stimulant ADHD medications via telehealth (subject to state telehealth laws and current federal rules for controlled substances). Physicians must:

• Hold an active medical license in the state where the patient is located
• Have DEA registration (for any controlled substances)
• Follow standard diagnostic and prescribing practices

Nurse Practitioners (NPs)

Nurse practitioner prescribing authority varies significantly by state:

Full Practice Authority States (20+ states including California, New York, Illinois, New Hampshire):NPs can independently prescribe all ADHD medications, including Schedule II stimulants, after meeting education and experience requirements (typically 3,600-4,000 clinical hours). These states recognize NPs as autonomous providers who don’t need physician oversight for prescribing.

Collaborative Practice States (including Florida, Pennsylvania, Alabama):NPs must have a collaborative agreement or practice protocol with a supervising physician. Within this framework, most can prescribe ADHD medications, though some states impose additional limits on Schedule II prescriptions (like Florida’s 7-day supply limit for Schedule II written by NPs).

Restricted Practice States (Georgia, Texas for outpatient Schedule II):Some states either prohibit NP prescribing of Schedule II entirely (Georgia) or limit it to specific settings like hospitals (Texas). In these states, you’ll need to see a physician for stimulant medications, though NPs can still prescribe non-stimulants like Strattera.

At Klarity Health, we match you with appropriately licensed providers in your state—whether that’s a physician or nurse practitioner—ensuring whoever treats you has the legal authority to prescribe the medications you need.

Physician Assistants (PAs)

PAs typically practice under collaborative agreements or supervision arrangements in all states. Their controlled substance prescribing authority generally mirrors that of NPs in their state, though some states impose slightly different restrictions. PAs can prescribe non-stimulant ADHD medications nationwide under appropriate supervision models.

The Telehealth ADHD Evaluation Process: What to Expect

Legitimate telehealth ADHD providers follow comprehensive evaluation protocols that rival—and sometimes exceed—typical in-person assessments.

Initial Consultation

Your first telehealth visit will likely include:

Symptom Assessment:

• Detailed questions about attention, focus, and concentration difficulties
• Questions about hyperactivity and impulsivity (if present)
• Evaluation of symptoms in multiple settings (work, home, relationships)
• Timeline of when symptoms first appeared (ADHD must have childhood onset)

Diagnostic Tools:

• Structured questionnaires based on DSM-5 criteria
• Rating scales for symptom severity (like the ASRS or Conners Adult ADHD Rating Scale)
• Sometimes input from family members or partners to corroborate symptoms
• Review of any previous ADHD evaluations or school records

Medical History:

• Current and past medications
• Other mental health conditions (anxiety, depression, bipolar disorder)
• Cardiovascular history and blood pressure
• Substance use history
• Family psychiatric history

Differential Diagnosis:Your provider will also consider other conditions that can mimic ADHD, such as:

• Anxiety disorders (which often co-occur with ADHD)
• Depression causing concentration difficulties
• Sleep disorders like sleep apnea
• Thyroid problems
• Side effects from other medications

Treatment Planning

If ADHD is confirmed, your provider will discuss treatment options:

Medication Considerations:

• Whether to start with a stimulant or non-stimulant
• Your preferences and concerns about specific medications
• Potential side effects and how to manage them
• Expected timeline for improvement
• Dosing schedule and titration plan

Non-Medication Approaches:Quality providers don’t just prescribe medication. They should also discuss:

• Behavioral strategies and organizational tools
• The potential benefit of therapy (especially CBT for ADHD)
• Lifestyle factors: sleep, exercise, caffeine use, stress management
• Accommodations at work or school if appropriate

Why Strattera Might Be Recommended First

Your telehealth provider might suggest starting with Strattera rather than a stimulant for several reasons:

1. Anxiety or Mood Concerns: If you have co-occurring anxiety or mood disorders, stimulants can sometimes worsen these symptoms. Strattera may actually help with emotional regulation.

2. Cardiovascular Issues: Patients with heart conditions, high blood pressure, or family history of cardiac problems may be better candidates for non-stimulants, which generally have milder cardiovascular effects.

3. Substance Use History: If you have a personal or family history of addiction, non-stimulants eliminate concerns about medication misuse or dependency.

4. Regulatory Simplicity: Especially in states with stricter telehealth rules for controlled substances, starting with a non-stimulant can expedite treatment while avoiding regulatory hurdles.

5. All-Day Coverage: Strattera provides consistent symptom control throughout the day without the peaks and valleys of short-acting stimulants, which some patients prefer for stable functioning.

Common Questions and Concerns About Telehealth ADHD Treatment

‘Will my pharmacy fill a telehealth prescription?’

Generally, yes. Electronic prescriptions don’t indicate whether your visit was conducted in person or via telehealth. Strattera prescriptions typically face no scrutiny since it’s not a controlled substance.

However, the 2023 controversies involving some online ADHD services (like Cerebral and Done) did make some pharmacists more cautious about controlled substance prescriptions from telehealth providers. Using a reputable service like Klarity Health—which follows rigorous clinical protocols—and maintaining a relationship with a consistent pharmacy can prevent any issues.

‘How long does Strattera take to work?’

Unlike stimulants that work within hours, Strattera requires patience. Most patients notice:

• 1-2 weeks: Possible side effects (nausea, decreased appetite, mild fatigue) as your body adjusts
• 2-4 weeks: Initial improvements in emotional regulation and impulse control
• 4-6 weeks: Full therapeutic effect on attention and focus symptoms
• 8-12 weeks: Continued improvement and stabilization

Your telehealth provider will schedule follow-up appointments to monitor your progress, adjust dosing if needed, and ensure the medication is both effective and well-tolerated.

‘What if Strattera doesn’t work for me?’

If Strattera doesn’t provide adequate symptom relief after a proper trial (usually 8-12 weeks at therapeutic dose), your provider has several options:

1. Try a different non-stimulant (like guanfacine or clonidine)
2. Switch to a stimulant medication if appropriate and legally permissible in your state
3. Combine medications (some patients benefit from both a non-stimulant and a stimulant)
4. Refer for additional evaluation if the diagnosis is uncertain or if there are complicating factors

Quality telehealth providers maintain flexibility in treatment approaches and will work with you to find the most effective option.

‘Do I need an ADHD diagnosis from childhood to get treatment?’

ADHD is defined as a neurodevelopmental disorder with childhood onset—technically, symptoms should be present before age 12. However, many adults weren’t diagnosed as children, especially women and people who primarily have inattentive-type ADHD without obvious hyperactivity.

Legitimate telehealth providers will ask about your childhood functioning, perhaps reviewing old report cards or talking with family members if available. The key is evidence that attention difficulties have been long-standing, not just recent stress-related problems. Adult ADHD diagnosis is nuanced, and good clinicians understand that lack of childhood diagnosis doesn’t mean you don’t have ADHD—it may mean you learned to compensate or weren’t recognized at the time.

‘Are there age restrictions for telehealth ADHD treatment?’

Most telehealth platforms, including Klarity Health, primarily serve adults (18+) or older adolescents (16-17 with parental consent). Young children typically require in-person pediatric evaluation for ADHD diagnosis, as the assessment process is more complex and may include school observations and developmental testing.

For teenagers and young adults, telehealth can be highly effective, especially when parents or guardians participate in the evaluation process to provide collateral information.

Red Flags: When Telehealth Might Not Be Appropriate

Responsible telehealth providers screen carefully to ensure virtual care is safe and appropriate. You may not be a good candidate for telehealth ADHD treatment if:

Medical Complexity

• Uncontrolled cardiovascular disease: Significant heart problems, recent heart attack, or severe uncontrolled hypertension may require in-person cardiology clearance before starting ADHD medications.

• Severe psychiatric conditions: Active psychosis, uncontrolled bipolar disorder, or recent hospitalization for mental health crisis typically need in-person specialty evaluation before ADHD treatment.

• Substance use disorder: Active addiction or very recent substance abuse (especially stimulants) may require in-person addiction medicine consultation and treatment before prescribing ADHD medications.

Diagnostic Uncertainty

• Complex presentation: If you have multiple overlapping conditions making diagnosis unclear, in-person comprehensive neuropsychological testing might be necessary.

• Suspected learning disabilities: Formal psychoeducational testing (which requires in-person assessment) may be needed to distinguish ADHD from learning disorders.

Behavioral Red Flags

Legitimate providers will decline or terminate care if they detect:

• Requests for specific controlled medications by name (especially with dosage requests)
• Refusal to try non-stimulants or resistance to non-medication approaches
• ‘Doctor shopping’ behavior or inconsistent medication stories
• Requests for early refills or lost prescription reports
• Unwillingness to provide complete medical history or consent to contact other providers

These aren’t about judging patients—they’re about ensuring safety and appropriate care.

The Current Scrutiny on Telehealth ADHD Services

What Happened with Cerebral and Done?

In 2022-2023, several high-profile telehealth companies faced federal investigations for allegedly over-prescribing stimulant medications without adequate oversight. These cases led to:

• DEA and DOJ investigations
• Some companies stopping controlled substance prescribing entirely
• Increased media scrutiny of the entire telehealth ADHD sector
• Tighter internal controls across the industry

How Legitimate Providers Responded

Reputable telehealth companies, including Klarity Health, responded by implementing even more rigorous protocols:

Enhanced Clinical Oversight:

• More detailed diagnostic evaluations
• Required documentation of ADHD criteria
• Regular quality assurance reviews of provider practices
• Limits on prescription quantities for new patients

Improved Safety Measures:

• Mandatory follow-up schedules (typically monthly for the first few months)
• Communication with patients’ primary care providers when possible
• Treatment agreements outlining expectations and responsibilities
• In some cases, urine drug screening for controlled substance prescriptions

Transparent Practices:

• Clear communication that medication isn’t guaranteed
• Emphasis on comprehensive care including therapy referrals
• Honest discussion of risks, benefits, and alternatives
• Explicit policies against early refills or dose escalation without clinical justification

What This Means for Patients

The increased scrutiny has actually made telehealth ADHD care more robust and trustworthy. When you work with a provider who follows these enhanced protocols, you’re receiving high-quality care that prioritizes your long-term wellbeing over short-term prescription fulfillment.

Cost and Insurance Coverage for Telehealth ADHD Treatment

Insurance Coverage

Most major insurance plans now cover telehealth at the same rate as in-person visits, thanks to COVID-era policy changes that many states made permanent. This includes:

• Evaluation and diagnosis visits
• Follow-up medication management appointments
• Therapy sessions (if applicable)

At Klarity Health, we accept both insurance and self-pay options, providing transparent pricing upfront so you know exactly what to expect. Many patients find that telehealth visits have lower copays than traditional in-person psychiatric appointments, and the convenience of not taking time off work often offsets any out-of-pocket costs.

Medication Costs

Non-stimulant medications like Strattera vary in cost:

• Generic atomoxetine: Typically $30-100/month with insurance, or $100-200 without insurance
• Brand-name Strattera: Can cost $300-400/month without insurance, though manufacturer coupons and patient assistance programs often reduce this significantly

Stimulant medications (if prescribed) tend to be more affordable, with many generics available for under $50/month even without insurance. However, insurance coverage can be more complex due to prior authorization requirements and quantity limits.

Provider Visit Costs

Typical pricing for telehealth ADHD visits:

• Initial evaluation: $150-300 (often covered by insurance with standard specialist copay)
• Follow-up visits: $75-150 (typically 15-30 minute appointments)
• Frequency: Monthly for the first 3-6 months, then every 2-3 months once stable

Klarity Health offers straightforward pricing with the flexibility to use insurance or pay directly—whichever works best for your situation.

Looking Ahead: The Future of Telehealth ADHD Treatment

Regulatory Outlook for 2026

The telehealth landscape will likely see significant changes in 2026:

Federal Level:The DEA is expected to either extend current flexibilities again or implement new permanent rules (possibly the proposed ‘Special Registration’ system for telehealth providers). The worst-case scenario—an abrupt return to strict in-person requirements—seems unlikely given bipartisan congressional support for telehealth access, but isn’t impossible.

For Non-Stimulant Patients:Regardless of what happens with controlled substance rules, non-stimulant prescribing via telehealth will remain legally straightforward. Strattera and similar medications are unlikely to face new restrictions since they’ve never been part of the controlled substance concerns driving regulatory scrutiny.

State Trends:More states are moving toward permanent telehealth frameworks. We’re seeing:

• Reduced in-person visit requirements (like New Hampshire’s 2025 update)
• Interstate licensure compacts expanding (making it easier for providers to treat patients across state lines)
• Telehealth parity laws becoming permanent
• However, continued tightening of PDMP requirements and controlled substance oversight

Technology Improvements

The telehealth experience continues to improve:

• Better video platforms with enhanced HIPAA compliance
• Integration with electronic health records for seamless care coordination
• More sophisticated diagnostic tools and rating scales delivered digitally
• Improved e-prescribing systems reducing pharmacy friction

The Klarity Health Advantage

At Klarity Health, we’re positioned to adapt to whatever regulatory changes emerge while maintaining uninterrupted care for our patients:

Provider Network:We maintain a network of licensed physicians and nurse practitioners across all 50 states, ensuring you can access care regardless of where you live or what prescribing rules apply in your state.

Treatment Flexibility:Whether you need a non-stimulant like Strattera, a stimulant medication, or a combination approach, our providers can create a treatment plan tailored to your needs and your state’s regulations.

Transparent Approach:We clearly communicate what to expect, including honest discussions about medication options, realistic timelines for improvement, and what responsibilities you’ll have in managing your treatment.

Integrated Care:Beyond prescribing, we can connect you with therapy resources and help coordinate with your primary care provider to ensure comprehensive treatment.

Making the Decision: Is Telehealth ADHD Treatment Right for You?

Telehealth ADHD treatment works exceptionally well for many patients, particularly:

✅ Adults with uncomplicated ADHD seeking initial treatment or continuing established care

✅ Patients in rural areas or locations with long wait times for psychiatric appointments

✅ Busy professionals who struggle to take time off for in-person appointments

✅ People comfortable with technology and video consultations

✅ Those preferring or requiring non-stimulant medications for medical or personal reasons

✅ Patients who value convenience and flexible scheduling

Telehealth might not be the best fit if:

❌ You have significant medical complexity requiring in-person evaluation

❌ You prefer face-to-face interactions or have technology barriers

❌ You have active substance use issues requiring intensive treatment

❌ Your state’s specific rules make telehealth logistically difficult

❌ You need extensive psychological testing for differential diagnosis

Taking the Next Step

If you’re ready to explore ADHD treatment through telehealth:

1. Research providers in your state—look for services with licensed clinicians, comprehensive evaluations, and transparent practices.

2. Gather information about your symptoms: When did they start? How do they affect different areas of your life? What have you tried before?

3. Prepare medical history: List current medications, past psychiatric treatments, relevant medical conditions, and family mental health history.

4. Schedule a consultation with a platform like Klarity Health that offers same-day or next-day appointments with licensed providers.

5. Be honest and thorough during your evaluation—the quality of your treatment depends on the information you provide.

6. Commit to follow-up care—ADHD treatment is most effective as an ongoing partnership, not a one-time prescription.

Getting Started with Klarity Health

Klarity Health makes accessing ADHD treatment straightforward, affordable, and personalized to your needs. Our providers are available across all 50 states, we accept both insurance and self-pay, and we offer flexible scheduling that fits your life—including evenings and weekends.

Whether you’re seeking a non-stimulant like Strattera or need to discuss all available treatment options, our licensed physicians and nurse practitioners conduct thorough evaluations and create individualized treatment plans. We’re here to support your journey toward better focus, productivity, and quality of life.

Ready to take the next step? Schedule your consultation with Klarity Health today and discover how accessible and effective ADHD treatment can be.

Citations

1. DEA Third Temporary Extension of COVID-19 Telemedicine Flexibilities – Federal Register (November 2024). Available at: www.fiercehealthcare.com

2. Telehealth and In-Person Visits: Tracking Federal and State Updates – Sheppard Mullin Healthcare Law Blog, National Law Review (August 15, 2025). Available at: www.sheppardhealthlaw.com

3. The Telehealth Compliance Trap: State-by-State Analysis – RxAgent Compliance Blog (October 2025). Available at: www.rxagent.co

4. Florida Statutes §456.47 – Telehealth and Controlled Substance Prescribing – Center for Connected Health Policy (November 2025). Available at: www.cchpca.org

5. Is Strattera a Controlled Substance? – Medical News Today (January 14, 2025). Medically reviewed. Available at: www.medicalnewstoday.com

Source:

• https://www.fiercehealthcare.com/regulatory/dea-finalizes-one-year-extension-controlled-substance-prescribing-telehealth-punts-final#:~:text=The%20Drug%20Enforcement%20Administration%20,Federal%20Register%20on%20Friday%20night
• https://www.mwe.com/insights/dea-signals-extension-of-telemedicine-flexibilities-for-controlled-substance-prescribing-for-2026/#:~:text=visit,examination%20through%20December%2031%2C%202025
• https://www.mwe.com/insights/dea-signals-extension-of-telemedicine-flexibilities-for-controlled-substance-prescribing-for-2026/#:~:text=A%20new%20rule%20posted%20on,date%20of%20December%2031%2C%202025
• https://www.fiercehealthcare.com/regulatory/dea-finalizes-one-year-extension-controlled-substance-prescribing-telehealth-punts-final#:~:text=The%20%E2%80%9CThird%20Temporary%20Extension%20of,14
• https://www.medicalnewstoday.com/articles/drugs-is-strattera-a-controlled-substance#:~:text=Strattera%20,such%20as%20mental%20health%20issues
• https://www.sheppardhealthlaw.com/2025/08/articles/telehealth/telehealth-and-in-person-visits-tracking-federal-and-state-updates-to-pandemic-era-telehealth-exceptions/#:~:text=In%20late%202024%2C%20the%20U,prescribing
• https://www.rxagent.co/blog/telehealth-compliance-trap#:~:text=The%20,False%20Hope
• https://www.techtarget.com/virtualhealthcare/news/366616019/Telehealth-prescribing-flexibility-extended-through-2025#:~:text=Image%20filo%2FDigitalVision%20Vectors%20via%20G,The
• https://natlawreview.com/article/telehealth-and-person-visits-tracking-federal-and-state-updates-pandemic-era?amp=#:~:text=Extend%20natlawreview,before%20issuing%20a%20dangerous%20drug
• https://www.rxagent.co/blog/telehealth-compliance-trap#:~:text=,specifically%20for%20chronic%20pain%20treatment